Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neurogene Inc NGNE

Healthcare Biotechnology
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT... see more

Recent & Breaking News (NDAQ:NGNE)

    Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

    Business Wire August 9, 2024

    Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

    Business Wire August 7, 2024

    Neurogene to Participate in BMO Genetic Medicines Summit

    Business Wire July 2, 2024

    Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    Business Wire June 18, 2024

    Neurogene to Participate in Upcoming Conferences

    Business Wire June 5, 2024

    Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

    Business Wire June 3, 2024

    Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

    Business Wire May 10, 2024

    Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

    Business Wire May 7, 2024

    Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

    Business Wire April 22, 2024

    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

    Business Wire March 18, 2024

    Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial

    Business Wire March 4, 2024

    Neurogene to Participate in Upcoming Investor Conferences

    Business Wire February 29, 2024

    Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

    Business Wire January 16, 2024

    Neurogene Announces Business Update and 2024 Outlook

    Business Wire January 5, 2024